AstraZeneca’s Antiplatelet Agent Brilinta Superior To Plavix In Phase III Trial

But Lilly/Daiichi’s pending Effient has done the same thing, albeit with increased bleeding. Full PLATO data, to be released in August, will be scrutinized for safety.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet